Item 7.01 Regulation FD Disclosure. On September 19, 2020, the European Society for Medical Oncology ("ESMO") published Pieris Pharmaceuticals, Inc.'s (the "Company") abstract related to its phase 1 dose escalation study of PRS-343, entitled "A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies." The abstract is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. On September 20, 2020, the Company presented its phase 1 dose escalation study of PRS-343 entitled "A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies" at the ESMO Virtual Congress 2020. The presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth under this "Item 7.01. Regulation FD Disclosure," including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing. except as shall be expressly set forth by specific reference in such filing.


--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.



99.1    PRS-343 Dose Escalating Study     Abstract, Dated September 19, 2020  .
99.2    PRS-343 Dose Escalating Study Presentation, Dated September 20 2020  .

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses